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Background: An HIV-1 tropism test is recommended prior to CCR5 antagonist administration to exclude patients
harboring non-R5 virus from treatment with this class of antiretrovirals. HIV-1 tropism determination based on proviral
DNA (pvDNA) may be useful in individuals with plasma viral RNA suppression. We developed a genotypic tropism assay
for pvDNA and assessed its performance in a retrospective analysis of samples collected longitudinally.
Results: We randomly selected paired plasma/PBMC samples from the Women’s Interagency HIV Study with plasma
viral load ≥5,000 cp/mL at time 1 (T1), undetectable viral load maintained for ≥1 year and CD4+ >200 cells/μL at time
2 (T2). pvDNA was isolated from cryopreserved PBMCs. Sequences were analyzed in triplicate from 49/50 women,
with tropism assigned using the geno2pheno (g2p) algorithm. The median time between T1 and T2 was 4.1 years.
CXCR4-using virus was detected in 24% of the RNA samples and 33% of the pvDNA samples at T1, compared to 37%
of the pvDNA samples at T2. Concordance between plasma RNA and pvDNA tropism was 88% at T1 and 80% at T2.
The g2p scores for RNA (T1) vs DNA (T1, T2) were strongly correlated (Spearman rho: 0.85 (T1); 0.78 (T2)). In women with
evidence of tropism switch at T2 (either R5 to non-R5 or non-R5 to R5), there was a correlation between change in
tropism and time. Mean pvDNA viral load decreased by 0.4 log10 copies/106 cells between T1 and T2 (p < 0.0001), but
this decrease was not significantly associated with tropism status.
Conclusions: We demonstrated that pvDNA tropism in women with HIV-1 suppression is concordant with prior RNA
tropism results, even after a median time of >4 years. pvDNA tropism testing may be useful to determine eligibility of
patients with viral suppression to switch to a CCR5-antagonist based regimen as well as for research purposes.
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Human immunodeficiency virus type 1 (HIV-1) infects
cells through interaction with the CD4 receptor and
one of two coreceptors, CCR5 or CXCR4 [1-3]. CCR5
coreceptor-using virus (R5 virus) predominates in 80-90%
of recently infected and treatment-naïve HIV-1 pa-
tients, while mixed populations of R5 virus and CXCR4
coreceptor-using virus (non-R5 or “X4” virus) are found
in up to 50% of late-stage and antiretroviral treatment
(ART)-experienced patients [4-10]. The presence of* Correspondence: Ron.M.Kagan@questdiagnostics.com
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unless otherwise stated.non-R5 virus is associated with lower CD4+ T-cell
counts, higher plasma viral loads, and more rapid pro-
gression to AIDS [6,9,11,12]. Small-molecule CCR5
antagonists such as maraviroc can effectively inhibit
the interaction of R5 HIV-1 with the CCR5 coreceptor
[3,13]. An HIV-1 coreceptor tropism test is required
prior to maraviroc administration, to exclude patients
harboring non-R5 virus from treatment with this drug
(Maraviroc prescribing information, https://www.gsksource.
com/gskprm/htdocs/documents/SELZENTRY-PI-MG.PDF).
Many HIV-1-infected individuals undergoing ART
achieve undetectable or low levels plasma HIV-1 RNA.
Because most plasma RNA tropism tests require at least
1,000 copies/mL of HIV-1 RNA to be present in order toral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be required to determine whether individuals with viral
suppression could benefit from the inclusion of a CCR5
antagonist in their ART regimen. In this situation, tropism
testing of archived HIV-1 proviral DNA (pvDNA) in
peripheral blood mononuclear cells (PBMC) can be per-
formed [14,15]. From a clinical standpoint, the ability to
determine tropism from pvDNA allows testing to be ex-
tended to persons who are taking effective antiretroviral
therapy but who may be candidates for CCR5 antagonist
therapy. This includes patients who are experiencing ad-
verse effects from their current regimen and patients re-
ceiving complex regimens who may benefit from regimen
simplification. A number of studies have shown strong
agreement between plasma RNA and pvDNA tropism
[16-20]. However, few studies have examined pvDNA
tropism longitudinally in individuals taking suppressive
ART [21-23], and most previous studies of HIV-1 tropism
have focused mostly on men [4,8,12,16].
We have developed a genotypic tropism assay that
uses triplicate PCR amplification of the HIV-1 envelope
V3 region, the major determinant of coreceptor tropism
[1,3], and Sanger sequencing of pvDNA isolated from
PBMCs [16]. Here we assessed its performance in a retro-
spective longitudinal analysis of samples from individuals
in the Women’s Interagency HIV Study (WIHS), an
ongoing long-term observational cohort study of 3,772
HIV-1 infected or at- risk women [24].
Results
Baseline characteristics
HIV-1 envelope V3 loop sequences from plasma RNA
and pvDNA at T1 and pvDNA at T2 were successfully
obtained from 49/50 HIV-positive women and 0/10 HIV-
negative control samples. The median interval between
time point T1 and T2 samples was 4.1 years (IQR: 2.6,
5.1 years). Baseline characteristics of the subjects are
shown in Table 1. There was no statistically significantTable 1 Subject Demographic, Virologic and Immunologic Pa
Coreceptor Tr
Median (IQR)1 All Subjects Concordant R
N 49 28
Age (years) 38 (33, 43) 39 (32,33)
Nadir CD4+(cell/uL) 191 (87, 269) 194 (106, 270)
T1 CD4+(cells/uL) 323 (243, 417) 321 (235, 404)
T1 viral load(log10 copies/mL) 4.8 (4.4, 5.3) 4.7 (4.2, 5.3)
Delta T1 and T2 (years) 4.1 (2.6, 5.1) 3.1 (2.3, 4.7)
T2 CD4+(cells/uL) 558 (365, 717) 576 (258, 747)
1T1: Time point 1, viremic subjects pre-suppression; T2: Time point 2, after subjects
2Concordant R5: CCR5-tropic viral RNA at T1 and proviral DNA at T1 and T2; Concor
Discordant: at least 1 discordant tropism result at T1 or T2.
3Kruskall-Wallis test for difference in distributions among tropism status categories.association between age, viral load at time point T1,
nadir CD4+ T-cell count, T-cell counts at either time
point or the interval between time points and the trop-
ism concordance status between pvDNA and plasma
RNA tropism tests (Table 1). Women with concordant
non-R5 pvDNA and plasma RNA tropism results ap-
peared to have a lower nadir CD4+ count (138 cell/uL
vs 194 cells/uL overall) but this difference was not sta-
tistically significant.Coreceptor tropism concordance between plasma RNA
and pvDNA
V3 sequences were classified as R5 for 57% (28/49) and
non-R5 for 20% (10/49) of the women for analyses of
both RNA (T1) and pvDNA (T1 and T2). Tropism results
were discordant for 11 women (Figure 1). Four women
had only R5 virus detectable in the plasma RNA sample
and pvDNA sample collected at T1 but detectable non-R5
virus in the later pvDNA sample from T2 (subjects 1, 2, 5
and 9). An additional four women had only R5 virus in
the plasma RNA sample collected at T1 and detectable
non-R5 virus for both pvDNA time points (subjects 3, 4,
7, 10). Two women had detectable non-R5 virus in both
the plasma RNA sample and the pvDNA sample at T1 but
only R5 virus was detected in the pvDNA sample at time
point T2 (6 and 11). The last discordant sample had only
detectable R5 virus in the plasma RNA sample at time
point T1, non-R5 virus in the T1 pvDNA sample, but only
R5 virus in the T2 pvDNA sample (subject 8). Phylogen-
etic tree analysis of the 11 discordant samples showed that
the T2 pvDNA sequences remained clustered with se-
quences from T1 from the same subject, illustrating that
they were closely related. The discordant non-R5 viruses
tended to appear on distinct branchings within each clus-
ter (Figure 1) showing that they were distinct yet related
phylogenetically. None of the discordant sequences clus-
tered with sequences from an unrelated patient indicatingrameters
opism Status2
5 Concordantnon-R5 Discordant p-value3
10 11
36 (32, 38) 40 (34, 44) 0.62
138 (44, 249) 191 (83, 285) 0.58
276 (234, 375) 345 (276, 537) 0.70
5.1 (4.5, 5.4) 4.8 (4.4, 5.3) 0.41
4.2 (2.7, 5.4) 4.3 (3.3, 6.2) 0.28
478 (294, 772) 532 (371, 666) 0.81
had undetectable viral load (<80 copies/mL) for ≥1 year.
dant non-R5: CXCR4-tropic viral RNA at T1 and proviral DNA at T1 and T2;
Figure 1 Phylogeny of V3 sequences for discordant tropism group. Blue circles: T1 R5. Red circles: T1 non-R5. Blue squares: TP2 R5. Red squares: T2 non-R5.
JRCSF: V3 loop of R5 reference sequence used as an outgroup. Subjects are consecutively numbered 1 – 11. The scale bar is shown in the upper left corner.
V3 sequences were aligned with ClustalX version 2.1 (http://www.clustal.org) and a neighbor-joining tree was generated using Kimura-corrected distances for
multiple substitutions. The tree was then rendered and illustrated with Denodroscope version 3.2.10 (http://ab.inf.uni-tuebingen.de/software/dendroscope/).
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the observed discordances.
A higher proportion of pvDNA samples were deter-
mined to have non-R5 tropism (33% at T1 and 37% at T2)
as compared to plasma RNA (24% at T1). The overall con-
cordance of tropism predictions between viral RNA and
pvDNA, however, was 88% (kappa = 0.70) at T1; concord-
ance was 80% (kappa = 0.53) at T2 (Table 2). pvDNA was
92% sensitive for non-R5 virus relative to plasma RNA at
T1 but the sensitivity was lower at T2 (83%) after a me-
dian interval of 4.1 years (Table 2). The geno2pheno FPR
scores for coreceptor tropism prediction were highly
correlated between RNA and pvDNA at T1 (Spearman
correlation coefficient rho = 0.85) and T2 (rho = 0.78), and
between the pvDNA results at T1 and T2 (rho = 0.85).
Lymphocyte counts and pvDNA copy number at T1 and T2
Although CD4+ cell counts did not differ significantly as
a function of tropism status, women with non-R5 virus
tended to have a lower CD4+ count (Table 1). Women
who had only R5 virus at both time points had the largest
gain in CD4+ cells (237 cells/μL) over that time period,
whereas women harboring non-R5 virus at both time
points had a smaller CD4+ cell count increase between
T1 and T2 (104 cells/μL). The women with discordant
tropism results (defined as having a tropism discordance
between either PBMC time point or plasma at T1 and one
of the PBMC timepoints), had a median increase of
169 cells/μL. For women with any non-R5 result at either
time point, the median increase was 159 cells/μL (IQR:
−4.0, +321; p = 0.049). The difference in CD4+ change be-
tween the R5 and non-R5 groups was not statistically sig-
nificant (p = 0.13; Additional file 1: Figure S1).
pvDNA copy number was also measured at both time
points. The mean pvDNA viral load decreased from 3.2 log10
copies/106 cells at T1 to 2.8 log10 copies/10
6 cells at T2, a sig-
nificant decline of 0.4 log10 copies/10
6 cells (p < 0.0001;
Additional file 2: Figure S2). Changes in proviral DNA
viral load were not significantly associated with baseline
tropism status.
Discussion
Investigation of viral evolution during suppressive ART
has not documented viral replication in an examination of
plasma [25]. Our study compared proviral V3 sequences
from PBMCs before and years after viral suppression. ThereTable 2 Concordance Between Plasma RNA and pvDNA Corec
Test Method Reference Method non-R5 (%) Test Ref.
pvDNA(T1) Plasma RNA(T1) 33% 24%
pvDNA(T2) Plasma RNA(T1) 37% 24%
1Sensitivity is defined as concordant non-R5s between the test and reference meth
2Specificity is defined as concordant R5s between the test and reference methods/r
3Kappa: a measure of inter-rater agreement; 0.41-0.60: moderate agreement; 0.61-0was no evidence of a tropism switch for 38 women with
HIV-1 suppression over a median of over 4 years. This
observation is consistent with low rates of viral evolution of
the V3 loop. Five women with viral suppression had evi-
dence of a tropism switch defined as discordance between
the pvDNA tropism results at the two time points, irre-
spective of the RNA tropism at T1. A potential explanation
for this phenomenon could be low level viral replication
that was below the limit of quantitation (80 copies/mL) of
the plasma viral load assays used in the WIHS. It is also
consistent with some viral replication persisting in cells
during viral suppression in plasma [21,26]. Clonal expan-
sion of latently infected cells during suppressive ART has
also been described [27]. Persistence of expanded clones is
often associated with viral integration in genes controlling
cell growth. This phenomenon could potentially alter the
proportion of non-R5 virus over prolonged periods of
virologic suppression. Two other studies that investigated
tropism evolution in suppressed patients found lower rates
of tropism switching of 7.1% (N = 128, median suppression
4 years) [28] and 9.5% respectively (N = 42, median sup-
pression 2 years) [21]. These studies however, were per-
formed on more recently supressed patients, used a viral
load cutoff of 50 copies/mL and included both male and
female subjects.
The sensitivity of pvDNA tropism determination at T2
with respect to plasma RNA after a median of 4.1 years
of virologic suppression was lower compared to that of
the pre-suppression sample T1. Next Generation Sequen-
cing (NGS) of HIV-1 plasma RNA has been shown to
predict virologic response to maraviroc as well as the
enhanced sensitivity Trofile phenotypic assay and with
greater sensitivity for minority non-R5 variants than
population sequencing [29-31]. However, the accuracy
of NGS for tropism prediction using pvDNA was much
lower than population sequencing due to lower specifi-
city [32,33]. Therefore, it is unlikely that NGS would
have resulted in improved tropism accuracy for the T2
pvDNA samples. The geno2pheno tropism algorithm that
has become the standard tropism prediction tool for geno-
typic tropism tests also has limitations. A study of plasma
viral variants obtained from the “Berlin Patient”, the first
patient to be cured of HIV through allogenic trans-
plantation, detected a minority non-R5 viral population by
ultradeep sequencing and geno2pheno analysis. This popu-
lation however, was unable to rebound after transplantation,eptor Tropism
Concord. (%) Sens. (%)1 Spec. (%)2 Kappa3
88% 92% 86% 0.70
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of these limitations, proviral DNA tropism determinations
have proven to be predictive of virologic response in both
retrospective studies of viremic patients and more recently
prospectively, when used to assign virologically suppressed
patients to a maraviroc-based or alternative regimen [33,35].
Conclusions
In summary, we studied HIV-1 tropism in infected women
and found good concordance between plasma RNA and
pvDNA coreceptor tropism results which persisted over
time: 80% of women had a pvDNA tropism result that
was concordant with the baseline plasma finding after a
median of 4.1 years and at least a year of viral suppression.
Detection of non-R5 virus was slightly more frequent in
pvDNA than plasma RNA, as has been observed previ-
ously [16,20,33]. This finding suggests that a pvDNA
tropism test may exclude slightly more individuals from
treatment with a CCR5 inhibitor. However, virtually all
women with detectable non-R5 virus in plasma had de-
tectable non-R5 virus in the contemporaneous pvDNA
sample, suggesting that pvDNA testing may be a prom-
ising screening option for individuals with HIV-1 sup-
pression. 63% of the women in this study had a pvDNA
tropism result of R5 at the time of virologic suppression
and would have been eligible to switch to a maraviroc-
based regimen. Genotypic tropism determination from
pvDNA is commercially available at a significantly lower
cost than phenotypic tropism testing and may thus allow
coreceptor tropism assessment to be extended in a cost ef-
fective manner to persons who are taking effective ART
but who are being considered for CCR5 antagonist ther-
apy. This includes patients who are experiencing adverse
effects from their current antiretroviral regimen and pa-
tients receiving complex regimens who may benefit from
regimen simplification. This assay may also have value as




Laboratory testing of WIHS participants is performed
during biannual visits and includes lymphocyte subset
counts, plasma HIV-1 RNA levels and other tests as de-
scribed [24]. We randomly selected a cohort of 50 paired
samples collected between 1994 and 2006 from WIHS
participants in the Bronx, NY and Washington, DC
study sites, meeting the following criteria: a plasma viral
load ≥5,000 cp/mL at timepoint 1 (T1), a subsequently
undetectable plasma viral load of <80 copies/mL that had
been maintained for ≥1 year, along with a CD4+ T-cell
count of >200 cells/μL at time point 2 (T2). Although
most recent studies utilize a viral load cutoff of 50 copies/
mL to assess virologic response, a viral load cutoff of80 copies/mL was selected to be consistent with the
limit of quantitation for viral load assays available at
the time that these study samples were collected. Ten
paired plasma and PBMC samples obtained by the WIHS
from HIV-negative women were included as negative
controls.
Plasma HIV RNA coreceptor tropism testing
RNA was isolated from archived plasma specimens
(MagNAPure LC automated extraction system, Roche
Diagnostics Corp) that were stored at ≤ −70°C. Tropism
was determined for 3 independent replicates of viral RNA,
by using RT PCR and nested PCR amplification of the
V3 loop region from the HIV-1 envelope gene, followed
by Sanger DNA sequencing as previously described [16,29].
Tropism assignments (R5 or non-R5) were made with the
geno2pheno algorithm [36] with a false positive rate (FPR)
of 10% (non-R5: ≤10%) the recommended cutoff when
triplicate tropism determinations are employed [14].
Proviral DNA coreceptor tropism testing
Total DNA was extracted from 0.2 mL of cryopreserved
PBMCs (MagNA Pure system, Large Volume MagNA Pure
LC DNA Isolation Kit, Roche Diagnostics Corp). Three in-
dependent replicates were amplified in 2 rounds of PCR
using the same primers that were used for RNA trop-
ism testing, followed by Sanger sequencing as previ-
ously described [16,29]. Tropism was assigned using
the geno2pheno algorithm [36] using the same cutoff
for RNA tropism (non-R5: ≤10%).
HIV-1 pvDNA quantitation was performed using a real-
time quantitative PCR kit (Human HIV-DNA qPCR
Detection kit, GeneMoRe, Modena, Italy) according to
the manufacturer's instructions.
Additional files
Additional file 1: Figure S1. Changes in CD4+ cell counts between
time points T1 and T2 (median, IQR, and range).
Additional file 2: Figure S2. pvDNA viral load assayed at T1 and T2
(mean and 95% CI [error bars]).
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